|
Synonyms: CSL-324 | CSL324
Compound class:
Antibody
Comment: Anumigilimab (CSL-324) is a clinical stage monoclonal antibody that targets colony stimulating factor 3 receptor (CSF3R). It was developed by CSL Behring for potential efficacy in inflammatory/autoimmune diseases. The heavy and light chain peptide sequences for anumigilimab are claimed in patent WO2012171057A1 [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Nash AD, Andrews AE, Baca M, Edwarda KM, Hardt MP, Panousis C, Dunlop FM. (2012)
Antibodies against g-csfr and uses thereof. Patent number: WO2012171057A1. Assignee: Csl Limited. Priority date: 13/06/2011. Publication date: 20/12/2012. |
